Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment.
Grijsen ML., Wit FWNM., Jurriaans S., Kroon FP., Schippers EF., Koopmans P., Gras L., Lange JMA., Prins JM., Primo-SHM Study Group None.
Temporary cART during primary HIV-infection (PHI) did not select for drug resistance mutations after treatment interruption and did not affect the subsequent virological response to long-term cART. Our data demonstrate that fear of drug resistance development is not a valid argument to refrain from temporary early treatment during PHI.